Molecular and Cellular Effect of Angiotensin 1-7 on Hypertensive Kidney Disease

Am J Hypertens. 2019 Apr 22;32(5):460-467. doi: 10.1093/ajh/hpz009.

Abstract

Background: Studies implicate that angiotensin 1-7 (Ang1-7) imparts protective effects in the kidney. However, its relevance in hypertensive kidney disease is not fully understood. The purpose of this study was to explore the role of Ang1-7 on renal damage/remodeling during hypertension and its potential underlying molecular-cellular mechanisms.

Methods: Hypertension was induced in adult Sprague-Dawley rats by infusion of aldosterone (ALDO; 0.75 μg/hour) for 4 weeks with or without co-treatment of Ang1-7 (1 mg/kg/day). Untreated rats served as controls. Systolic blood pressure was monitored by tail-cuff technique. Renal fibrosis was evaluated by picrosirius red staining and renal collagen volume fraction was quantitated using imaging analyzing system. The expression of profibrotic factors [transforming growth factor-β1 (TGF-β1), platelet-derived growth factor-D (PDGF-D), fibroblast growth factor-1 (FGF-1), vascular endothelial growth factor-D (VEGF-D), and tissue inhibitors of metalloproteinases (TIMPs)] and free radical producing enzymes (inducible nitric oxide synthase and nicotinamide adenine dinucleotide phosphate [NADPH] oxidase) in the kidney were examined by reverse transcription-polymerase chain reaction and western blot. Renal oxidative stress was assessed by malondialdehyde (MDA) measurement.

Results: Chronic ALDO infusion caused hypertension and hypertensive renal disease represented as glomerular damage/sclerosis. Ang1-7 co-treatment did not affect blood pressure in ALDO-treated rats, but significantly attenuated the glomerular damage/fibrosis. ALDO treatment significantly elevated renal expression of profibrogenic factors, including TGF-β1, TIMP-1/TIMP-2, FGF-1, PDGF-D, and VEGF-D, whereas Ang1-7 co-treatment significantly reduced renal TGF-β1, TIMP-1/TIMP-2, and FGF-1, but not PDGF-D and VEGF-D. Furthermore, ALDO infusion elevated NADPH oxidase (gp91phox) and MDA in the kidney, which was attenuated by Ang1-7 co-treatment.

Conclusions: Ang1-7 plays a protective role in the hypertensive kidney disease independent of blood pressure. The beneficial effects of Ang1-7 are likely mediated via suppressing TGF-β/FGF-1 pathways and oxidative stress.

Keywords: angiotensin 1–7; blood pressure; fibrotic mediators; hypertension; hypertensive kidney disease; oxidative stress.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Angiotensin I / pharmacology*
  • Animals
  • Antihypertensive Agents / pharmacology
  • Blood Pressure / physiology
  • Blotting, Western
  • Disease Models, Animal
  • Fibrosis / genetics
  • Fibrosis / metabolism
  • Fibrosis / pathology
  • Gene Expression Regulation
  • Hypertension, Renal / drug therapy*
  • Hypertension, Renal / metabolism
  • Hypertension, Renal / pathology
  • Kidney / drug effects
  • Kidney / metabolism*
  • Kidney / pathology
  • Lymphokines / biosynthesis
  • Lymphokines / genetics
  • Male
  • Nephritis / drug therapy*
  • Nephritis / metabolism
  • Nephritis / pathology
  • Oxidative Stress*
  • Peptide Fragments / pharmacology*
  • Platelet-Derived Growth Factor / biosynthesis
  • Platelet-Derived Growth Factor / genetics
  • RNA / genetics
  • Rats
  • Rats, Sprague-Dawley
  • Tissue Inhibitor of Metalloproteinases / biosynthesis
  • Tissue Inhibitor of Metalloproteinases / genetics
  • Vascular Endothelial Growth Factor D / biosynthesis
  • Vascular Endothelial Growth Factor D / genetics

Substances

  • Antihypertensive Agents
  • Lymphokines
  • Pdgfd protein, rat
  • Peptide Fragments
  • Platelet-Derived Growth Factor
  • Tissue Inhibitor of Metalloproteinases
  • Vascular Endothelial Growth Factor D
  • RNA
  • Angiotensin I
  • angiotensin I (1-7)

Supplementary concepts

  • Hypertensive Nephropathy